Details for New Drug Application (NDA): 022344
✉ Email this page to a colleague
NDA 022344 describes LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, which is a drug marketed by Aurobindo Pharma Ltd and is included in one NDA. Additional details are available on the LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE profile page.
The generic ingredient in LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE is lamivudine; tenofovir disoproxil fumarate. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lamivudine; tenofovir disoproxil fumarate profile page.
The generic ingredient in LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE is lamivudine; tenofovir disoproxil fumarate. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lamivudine; tenofovir disoproxil fumarate profile page.
Summary for 022344
| Tradename: | LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE |
| Applicant: | Aurobindo Pharma Ltd |
| Ingredient: | lamivudine; tenofovir disoproxil fumarate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 300MG;300MG | ||||
| Approval Date: | May 15, 2018 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
